SCHEMBL2837332

SCHEMBL2837332

Cc1ccc(C(NC(=O)OC(C)(C)C)C(=O)c2ccc(O[Si](C)(C)C(C)(C)C)cc2)cc1F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.40
TRPA1 O75762 1/20 0.38
GABRB1 P18505 1/20 0.38
GABRB2 P47870 1/20 0.38
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
MDM2 Q00987 3/20 0.34
LMNA P02545 4/20 0.34
KMT2A Q03164 4/20 0.34
MEN1 O00255 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 3/20 0.33
HTT P42858 2/20 0.33
AAK1 Q2M2I8 1/20 0.33
PREP P48147 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2835071 0.88 S1PR3 (0.41) S1PR3TRPA1GABRB1GABRB2CTSS
SCHEMBL2832188 0.84 TRPA1 (0.42) S1PR3TRPA1GABRB1GABRB2CTSS
SCHEMBL2833970 0.84 S1PR3 (0.48) S1PR3TRPA1GABRB1GABRB2CTSS
SCHEMBL2832212 0.83 TRPA1 (0.41) S1PR3TRPA1GABRB1GABRB2CTSS
SCHEMBL2841519 0.83 S1PR3 (0.47) S1PR3TRPA1CTSSCTSKMDM2
SCHEMBL2842329 0.81 ALDH1A1 (0.38) S1PR3TRPA1GABRB1GABRB2ALDH1A1
SCHEMBL2839359 0.77 S1PR3 (0.44) S1PR3TRPA1GABRB1GABRB2CTSS
SCHEMBL17630124 0.74 TRPA1 (0.52) TRPA1CTSSCTSKLMNAALDH1A1
SCHEMBL17630127 0.74 TRPA1 (0.52) TRPA1CTSSCTSKLMNAALDH1A1
SCHEMBL17630006 0.74 TRPA1 (0.39) TRPA1GABRB1GABRB2CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885TRPA1 3113/4885GABRB1 536/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885TRPA1 3113/4885GABRB1 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.